Connecting the dots of anktiva's triangle offense: a deep dive with dr. patrick soon-shiong and dr. ashish kamat in a three-part urotoday podcast

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx) today announced the publication of three podcasts with urotoday highlighting the company's recent fda approval of anktiva® (n-803, or nogapendekin alfa inbakicept-pmln) plus bacillus calmette-guÉrin (bcg) for non-muscle invasive bladder cancer (nmibc) carcinoma in situ (cis) and advances in bladder cancer research. patrick soon-shiong, m.d., executive chairman and global chief scientific at immunitybio, discussed the breakin.
IBRX Ratings Summary
IBRX Quant Ranking